Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C plus V): a pooled analysis

被引：0

作者：

Lewis, K. ^{[1
]}

Larkin, J. ^{[2
]}

Ribas, A. ^{[3
]}

Flaherty, K. T. ^{[4
]}

McArthur, G. A. ^{[5
]}

Ascierto, P. A. ^{[6
]}

Dreno, B. ^{[7
]}

McKenna, E. ^{[8
]}

Zhu, Q. ^{[9
]}

Mun, Y. ^{[8
]}

Hauschild, A. ^{[10
]}

机构：

[1] Univ Colorado, Comprehens Canc Ctr, Med, Aurora, CO USA

[2] Royal Marsden Hosp NHS Fdn Trust, Oncol, London, England

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA

[4] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA

[5] Peter MacCallum Canc Ctr, Dept Med Oncol, East Melbourne, Australia

[6] Ist Nazl Tumori Fdn Pascale, Canc Immunotherapy & Innovat Therapy Unit, Melanoma, Naples, Italy

[7] Nantes Univ, Dermatol, Nantes, France

[8] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA

[9] Genentech Inc, Oncol, San Francisco, CA 94080 USA

[10] Univ Hosp Schleswig Holstein, Dermatol, Kiel, Germany

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1241P

引用

页数：1

共 50 条

[41] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
Gao, Tianfu
Liu, Jia
Wu, Jing
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
[42] Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study
Hauschild, A.
Chapman, P. B.
Robert, C.
Larkin, J.
Haanen, J. B.
Ribas, A.
Hogg, D.
Hamid, O.
Ascierto, P. A.
Testori, A.
Lorigan, P.
Dummer, R.
Sosman, J. A.
Flaherty, K. T.
Wongchenko, M. J.
Yan, Y.
Chang, I.
Coleman, S.
Caro, I.
Mcarthur, G. A.
MELANOMA RESEARCH, 2016, 26 : E39 - E40
[43] COMPARISON OF PREDICTED OVERALL SURVIVAL TO OBSERVED CLINICAL DATA IN PATIENTS WITH BRAF V600-MUTANT METASTATIC MELANOMA TREATED WITH ENCORAFENIB ALONE OR ENCORAFENIB plus BINIMETINIB
Hahn, E.
Rashid, J.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S19 - S19
[44] Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice.
Alamo de la Gala, Maria Carmen
Ochenduszko, Sebastian
Crespo, Guillermo
Corral, Monica
Oramas Rodriguez, Juana Maria
Pilar Sancho, Maria
Medina, Javier
Garicano Goldaraz, Fernando
Lopez Leiva, Pedro
Campos Balea, Begona
Adela Rodriguez, Analia
Munoz-Couselo, Eva
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[45] TRILOGY/IMspire150: A phase 3, double-blinded, randomized study of atezolizumab (A) plus cobimetinib (C) combined with vemurafenib (V) vs. placebo plus C combined with v in previously untreated BRAFV600 mutation-positive patients with locally advanced or metastatic melanoma (NCT02908672/EudraCT 2016-002482-54)
Ascierto, P.
Lewis, K.
McArthur, G.
Rooney, I.
McNally, V.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 46 - 47
[46] B-Raf V600E harboring non-melanoma cancers treated with Vemurafenib monotherapy and in combination with Everolimus/Sorafenib/Crizotinib/Paclitaxel plus Carboplatin: A pooled analysis of five phase 1/2 studies
Nelson, Blessie Elizabeth
Roszik, Jason
Janku, Filip
Hong, David
Kato, Shumei
Naing, Aung
Piha-Paul, Sarina
Fu, Siqing
Tsimberidou, Apostolia
Cabanillas, Maria
Busaidy, Naifa
Javle, Milind
Byers, Lauren
Heymach, John
Meric-Bernstam, Funda
Subbiah, Vivek
CANCER RESEARCH, 2022, 82 (12)
[47] Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma.
Chapman, Paul B.
Hauschild, Axel
Robert, Caroline
Larkin, James M. G.
Haanen, John B. A. G.
Ribas, Antoni
Hogg, David
Hamid, Omid
Ascierto, Paolo Antonio
Testori, Alessandro
Lorigan, Paul
Dummer, Reinhard
Sosman, Jeffrey Alan
Garbe, Claus
Maio, Michele
Nolop, Keith B.
Nelson, Betty J.
Joe, Andrew K.
Flaherty, Keith T.
McArthur, Grant A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[48] Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study
Dreno, Brigitte
Ascierto, Paolo Antonio
McArthur, Grant A.
Atkinson, Victoria
Liszkay, Gabriella
Di Giacomo, Anna Maria
Mandala, Mario
Demidov, Lev V.
Stroyakovskiy, Daniil
Thomas, Luc
De la Cruz-Merino, Luis
Dutriaux, Caroline
Garbe, Claus
Rooney, Isabelle Anne
Hsu, Jessie J.
Park, Erica
Ribas, Antoni
Larkin, James M. G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[49] Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) plus vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma.
Robert, Caroline
Lewis, Karl D.
Ascierto, Paolo Antonio
Munhoz, Rodrigo Ramella
Liszkay, Gabriella
de la Cruz-Merino, Luis
Olah, Judit
Queirolo, Paola
Mackiewicz, Jacek
Caro, Ivor
Shah, Kalpit
Forbes, Harper
Li, Haocheng
Hertig, Christian
Yan, Yibing
Mckenna, Edward Francis
Gutzmer, Ralf
McArthur, Grant A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] PROGNOSTIC FACTORS ASSOCIATED WITH REAL WORLD PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA TREATED WITH COBIMETINIB COMBINED WITH VEMUIRAFENIB, USING SURVIVAL DECISION TREE TECHNIQUE
Meyer, N.
Perol, D.
Duval-Modeste, A. B.
El Adaoui, L.
Lelarge, Y.
Niarra, R.
Pau, D.
Vauleon, T.
Gilberg, M.
Mateus, C.
VALUE IN HEALTH, 2019, 22 : S435 - S435

← 1 2 3 4 5 →